28

nanotimes

Companies Facts

for enabling computer chips to communicate using pulses of light instead of electrical signals, which can deliver increased performance of computing systems. http://www.youtube.com/watch?v=WBkvzubVyOY

I

llumina, Inc. (NASDAQ: ILMN) announced MiSeq™, a low-cost personal sequencing system that pro-

vides individual researchers a platform with rapid turnaround time, unmatched accuracy, and radically improved ease of use. Leveraging the company‘s TruSeq™ sequencing chemistry, the system‘s revo- lutionary workflow offers the flexibility to go from purified DNA to analyzed data in as few as eight hours, or to generate in excess of 1 gigabase per run in slightly over a day. Expected to be priced under $125,000 with individual run prices ranging from $400-$750, MiSeq will be the most affordable next- generation sequencing (NGS) platform available. Illumina expects to take initial orders for the MiSeq™ platform starting in April 2011 and anticipates ship- ping the first commercial units of MiSeq in summer 2011.

Furthermore, Illumina has acquired Epicentre Biotechnologies, a leading provider of nucleic acid sample preparation reagents and specialty enzymes used in sequencing and microarray applications. A key component of the acquisition is direct access to Epicentre‘s proprietary Nextera™ technology for next-generation sequencing library preparation, which greatly simplifies genetic analysis workflows and reduces time from sample preparation to an- swer.

Illumina announced preliminary revenue for the fourth quarter of 2010 of approximately $260 milli- on. This implies fiscal year 2010 revenue of appro-

ximately $901 million or annual growth of 35%. The Company also announced preliminary non-GAAP earnings per share for the fourth quarter and fiscal year 2010 between $0.28 and $0.29 and $1.05 and $1.06, respectively. The Company expects revenue growth for the full year 2011 of approximately 20% from anticipated 2010 revenue of $901 million and non-GAAP earnings per share to grow more than 30% from anticipated 2010 non-GAAP earnings per share between $1.05 and $1.06. http://www.illumina.com/miseq

I

nhibOx Ltd, based in Oxford, U.K., the specialist in novel and effective computational methods for

drug discovery, launched Scopius-5 – the world‘s largest currently available drug discovery scree- ning database and the first system to pass 100 milli- on compounds. Scopius-5 is a unique and powerful resource that will enable new levels of innovation and rigor to screening processes in drug discovery.

The Scopius-5 database platform stores many details of selected compounds, invaluable to those working in drug discovery. They include: multiple-conformati- on 3D models, shape and charge descriptors, pro- perty values and compound availability information, and/or synthetic route details. To ensure their useful- ness in discovery projects, entries are filtered against a set of drug-likeness criteria - structural and physical properties known to be common to almost all phar- maceutical compounds.

Scopius-5 consists of more than 110 million entries in three distinct sections, each enabling different approaches to lead identification and optimization studies. Scopius-5 is able to support very large-scale virtual screening studies at practical speeds because

11-01 :: December 2010 / January 2011